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Background: Data regarding the quantitative expression of TCR Vβ subpopulations in children with
autoimmune diseases provided interesting and sometimes conflicting results. The aim of the present study was
to assess by comparative flow cytometric analysis the peripheral blood CD4+ TCR Vβ repertoire of children with an
organ-specific autoimmune disorder, such as type 1 diabetes mellitus (T1DM), in comparison to children with a
systemic autoimmune disease, such as Systemic Lupus Erythematosus (SLE) in comparison to healthy age-matched
controls of the same ethnic origin. The CD4+ TCR Vβ repertoire was analysed by flow cytometry in three groups of
participants: a) fifteen newly diagnosed children with T1DM (mean age: 9.2 ± 4.78 years old), b) nine newly
diagnosed children with SLE, positive for ANA and anti-dsDNA, prior to treatment (mean age: 12.8 ±1.76 years old)
and c) 31 healthy age-matched controls (mean age: 6.58 ± 3.65 years old), all of Hellenic origin.
Results: CD4 + TCR Vβ abnormalities (± 3SD of controls) were observed mainly in SLE patients. Statistical analysis
revealed that the CD4 + Vβ4 chain was significantly increased in patients with T1DM (p < 0.001), whereas CD4 + Vβ16
one was significantly increased in SLE patients (p < 0.001) compared to controls.
Conclusions: CD4 + Vβ4 and CD4 + Vβ16 chains could be possibly involved in the cascade of events precipitating
the pathogenesis of T1DM and SLE in children, respectively.
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Autoimmunity involves complex pathophysiological
processes; however, no comprehensive model of inflam-
matory induction has been unraveled as yet. Genetic
and environmental immunologic factors, several hor-
mones and stress have been implicated in the pathogen-
esis of autoimmune disorders [1-4]. Moreover, the T cell* Correspondence: fltzifi@med.uoa.gr
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reproduction in any medium, provided the orreceptor (TCR), with its extended repertoire derived
from somatic recombination mechanisms, plays a po-
tential role in human autoimmune disease [5]. Animal
and human genetic studies have shown that skewing of
TCR Vβ repertoire is a characteristic feature of some
autoimmune disorders although still controversy exists
on that issue [6,7].
TCR Vβ repertoire is assessed with two methodolo-
gies, CDR3 spectratyping, which is a genetic assay that
provides mainly qualitative information about TCR Vβ
clonality [8,9], and flow cytometry analysis, which pro-
vides a quantitative assessment of TCR Vβ clones and is
well established in the clinical setting [10,11]. In T cell-
mediated organ-specific autoimmune diseases, such as
type 1 diabetes (T1DM), TCR Vβ repertoire analysis,. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 CD4 + Vβ repertoire usage in healthy children
Vb subfamily Mean percentage min (%) max(%) SD
Vb1 3.21 1.8 4.9 .66
Vb2 7.86 4 12.8 2.33
Vb3 4.23 1 8.5 2.22
Vb4 .76 .0 2.3 .58
Vb5.1 4.43 1.8 6.9 1.48
Vb5.2 1.39 .5 4.8 .97
Vb5.3 1.69 .6 3.5 .73
Vb7.1 1.85 .4 4.1 .89
Vb7.2 1.71 .0 4.9 1.07
Vb8 3.95 2 6.4 1.02
Vb9 2.90 .8 12.6 2.13
Vb11 1.49 .4 2.9 .70
Vb12 4.44 1.6 9.7 1.65
Vb13.1 4.23 2.1 7.4 1.35
Vb13.2 2.58 .2 6.8 1.42
Vb13.6 1.86 .8 3.5 .61
Vb14 4.00 1.4 9.6 1.78
Vb16 2.03 .6 5.1 .99
Vb17 3.88 .1 5.4 1.33
Vb18 1.34 .2 3.9 .90
Vb20 4.08 1.2 7.6 1.75
Vb21.3 2.47 .7 3.6 .71
Vb22 2.84 .7 7.5 1.26
Vb23 1.17 .2 4 .90
TOTAL: 70.39 (CD4+).
CD4 + TCR Vβ repertoire usage in 31 healthy Greek Children. Minimum (min)
and maximum (max) values obtained, as well as the mean percentages of the
24 CD4+ TCR Vβ chains are displayed. SD standard deviation.
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conflicting findings [12,13]. In systemic autoimmune dis-
eases, like Systemic Lupus Erythematosus (SLE), TCR Vβ
analysis has been conducted in adult populations using
the spectratyping method and a marked oligoclonality of
the TCR Vβ repertoire has been reported, which is more
prominent in patients with active disease [14,15]. It is
likely that children with SLE display a similar phenotype,
although no data exist regarding the expression of the Vβ
chains in the pediatric population. The marked skewing
of the TCR Vβ repertoire observed in some SLE pa-
tients has not been found in T1DM patients, although a
comparative study in a pediatric population between an
organ-specific disease, such as T1DM, and a systemic auto-
immune one, such as SLE, to our knowledge, has not been
conducted as yet.
The aim of this study was to compare the peripheral
blood CD4+ TCR Vβ repertoire in children with T1DM
and SLE, in comparison to healthy age-matched controls




Complete blood count values, immunoglobulin levels
and lymphocyte subpopulation counts were normal in all
healthy children. Autoantibodies, either SLE-specific or
diabetes speficic (ANA, anti-dsDNA, ICA), were evaluated
and they were negative in all controls tested. There was an
unavoidable male preponderance in the tested children
(boys: 80.6%), due to the higher frequency of anatomical
abnormalities needing surgical reconstruction in boys.
Mean values and standard deviations (SD) of each dis-
tinct Vβ family percentage on CD4+ lymphocytes of the 31
studied children are shown in Table 1. TCR Vβ usage ap-
pears to be non-random varying from low values of 0.0%
for Vβ4 and Vβ7.2 to high values of 12.8% for Vβ2. Add-
itionally, in one individual the value of the Vβ7.2 chain was
0.0%. The known polymorphism (null expression) in Vβ20
subfamily was not detected in the population tested.
The increased/decreased usage of a Vβ subfamily has
arbitrarily been defined as mean value ± 2 or 3 standard
deviations (mean value is the one derived from the con-
trol sample of the present study) [10,11]. Of the children
tested, 16 individuals had increased usage (expressed as
mean value + 2 or 3SD) of one or more Vβ lymphocyte
populations and these findings concerned different Vβ
chains in each subject. Seven children had an increased
usage of mean value + 2SD and nine an increased usage
of mean value + 3SD. Of these 16 subjects, 11 controls
presented with an increased usage in only one chain
(Vβ1, Vβ3, Vβ5.1, Vβ5.2, Vβ5.3, Vβ7.1, Vβ12, Vβ14, Vβ16,
Vβ20, Vβ22), 4 controls had increased usage in two Vβ
subpopulations (Vβ4-Vβ2, Vβ5.1-Vβ21.3, Vβ13.1-Vβ13.6,Vβ7.2-Vβ13.2 ) and one control in five ones (Vβ5.2, Vβ7.4,
Vβ8, Vβ9, Vβ18) (Figure 1). No discrepancies were noticed
in the Vβ11 and Vβ17 chains.
Enrolled infants and children were separated into three
age groups, which were compared in order to find out
possible differences in Vβ expression at different age
groups. Table 2 displays median values and interquartile
range of the CD4+ TCR Vβ repertoire in the aforemen-
tioned subgroups as well as in the total population of the
study. Statistical analysis revealed no significant differ-
ence for each of the 24 TCR Vβ subfamilies in the CD4+ T
lymphocytes.
b) T1DM children
Assessment of the CD4+ TCR Vβ repertoire was per-
formed in two ways: a) Vβ repertoire of each T1DM pa-
tient was compared with the Vβ mean values of the
control group and b) statistical analysis was performed,
Figure 1 CD4 + TCR Vβ chains quantitative expression in healthy children. CD4 + TCR Vβ repertoire usage (values %) in healthy controls
revealed that increased usage of Vβ subpopulations can be observed sporadically even in healthy children.
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clones in the group of T1DM patients with different
quantitative expression in comparison to the control
group.
The increased/decreased usage of a Vβ subfamily was
defined as control mean value ± 2 or 3 standard devia-
tions [10,11]. Five patients (33%) presented no abnor-
malities in all CD4 + Vβ chains values when compared
to controls (Table 3, Figure 2). One T1DM patient had
decreased usage of Vβ14 (0.7%, mean value: 4.00 ± 1.78)
and in another one Vβ20 value was 0.1% (mean value:
4.08 ± 1.75). None of the healthy individuals had such
low usage of these Vβ chains. Increased usage of several
CD4 + Vβ chains (Vβ3, Vβ4, Vβ5.1, Vβ5.3, Vβ8, Vβ11,
Vβ18, Vβ16 and Vβ21.3) was identified sporadically in
T1DM patients. With the exception of Vβ11 chain, in-
creased usage of the mentioned Vβ subpopulations were
also found in healthy individuals. Although the CD4 +
Vβ4 lymphocyte population increased usage was found
in 5 T1DM patients when compared to the mean value
of controls, statistical analysis showed a significant dif-
ference between the two groups (p < 0.001) concerning
the CD4 + Vβ4 subfamily (Table 4, Figure 3). This is
expected, since values of the controls ranged between
0.0% and 2.1% while T1DM values ranged from 0.6% to
3.3%. It should be mentioned that 17 healthy children
had values of the CD4 + Vβ4 chain < 1% and 12 T1DM
children had values > 1% (Figure 4). Taking into account
the very low number of CD4 + Vβ4 cells analyzed andthat the maximum coefficient of variation (CV) was 20%,
statistical analysis was adjusted to this CV. As shown in
Table 5, the differences remained significant even after
“narrowing” the mean values, adjusting for a 20% differ-
ence in the mean values of our measurements.
c) SLE children
In the SLE group, skewing in CD4 + Vβ subpopulations
was detected in the majority of patients when compared
to healthy individuals. In contrast to healthy children
and T1DM patients, which presented with a similar
CD4 + TCR Vβ repertoire pattern, 7 of the 9 SLE children
tested displayed concurrently marked increased (mean
value ± 3SD) and decreased usage (with even values of
0.0%) of several CD4 +Vβ subpopulations. This was note-
worthy in one SLE patient who displayed increased usage
of the CD4+ Vβ12 (9.44%), Vβ16 (5.6%) and Vβ20 (9.17%)
and a decreased one of Vβ2 (2.83%) and Vβ5.1 (0.12%)
chains and in another one patient with high values of
CD4+ Vβ3 (9%), Vβ12 (14.2%) and Vβ16 (7.3%) chains
and very low values of CD4+ Vβ2 (0.2%), Vβ5.2 (0.2%),
Vβ7.1 (0.1%) and Vβ22 (0.3%) (Table 6, Figure 5). Mark-
edly low values were found in the following CD4 + Vβ
chains: Vβ2 (in 2 patients), Vβ22 (in 2 patients), Vβ5.1,
Vβ5.2, Vβ7.1, Vβ8, Vβ13.6, and Vβ18. The CD4 + Vβ4
subpopulation had values of 0.0% in three SLE patients.
However, this finding, as previously mentioned, was no-
ticed in healthy children as well. Increased usage of Vβ16
was found in 5, of Vβ4 in 2, of Vβ20 in 2 and of Vβ12 in




18 months-4 years 5-9 years 10-14 years Total
Median IQR* p(18 m-4/5-9)† Median IQR* p(5-9/10-14) Median IQR* p(18 m-4/10-14) Median IQR* p(overall)
Vβ3 4.70 3.10 .080 3.35 2.90 .121 5.20 2.60 .831 4.40 3.60 .156
Vβ5.3 1.50 .70 .692 1.35 .90 .033 2.30 .90 .059 1.60 1.10 .068
Vβ7.1 1.50 .85 .643 1.25 .90 .022 2.60 1.20 .050 1.60 1.50 .048
Vβ16 1.70 1.10 .972 2.10 1.00 .248 2.50 1.40 .319 1.95 1.40 .472
Vβ9 2.35 1.30 .915 2.70 1.60 .825 2.60 1.40 .943 2.50 1.40 .984
Vβ17 4.05 1.85 .695 3.90 1.70 .690 4.30 1.80 .337 4.20 1.70 .652
Vβ20 3.35 1.70 .339 4.10 3.10 .838 5.10 2.30 .145 3.80 3.00 .346
Vβ18 .85 .90 .427 1.15 .80 .093 2.10 1.20 .027 1.20 1.50 .063
Vβ5.1 3.85 1.65 .448 4.85 3.00 .935 4.00 2.80 .670 4.20 2.30 .767
Vβ8 4.00 1.30 .741 4.00 1.80 .236 3.70 1.40 .374 3.90 1.60 .472
Vβ13.1 3.90 1.30 .692 3.75 2.10 .595 4.20 1.10 .859 3.90 1.50 .856
Vβ13.6 1.55 .60 .128 1.85 .70 .594 2.10 .50 .058 1.80 .80 .116
Vβ12 4.70 1.65 .717 4.50 2.10 .462 4.20 2.50 .125 4.50 1.80 .367
Vβ5.2 1.05 .90 .643 1.10 .50 .712 1.20 .90 .617 1.10 .90 .824
Vβ2 7.90 3.25 .448 6.95 3.80 .513 7.60 3.10 .722 7.40 3.70 .688
Vβ21.3 2.35 .95 .222 2.65 1.00 .967 2.80 .70 .319 2.60 1.00 .418
Vβ23 .80 .65 .740 .75 1.10 .189 1.30 1.50 .074 .80 1.10 .188
Vβ1 3.10 .55 .425 3.25 .70 .594 3.50 1.10 .198 3.10 .80 .414
Vβ14 4.20 1.75 .306 3.50 1.90 .967 3.70 1.50 .226 3.70 2.00 .418
Vβ11 1.20 .95 .921 1.50 .90 .190 1.80 1.40 .212 1.40 1.00 .342
Vβ22 2.70 1.20 .766 2.55 1.10 .165 3.10 1.40 .269 2.70 1.10 .348
Vβ7.2 1.35 1.70 .113 2.25 1.90 .487 1.70 1.10 .355 1.70 1.70 .261
Vβ13.2 1.85 .95 .129 2.80 1.80 1.000 2.40 .30 .042 2.20 1.50 .110
Vβ4 .85 .65 .741 .70 .70 .411 .50 .90 .238 .70 .80 .484
No age-related differences in CD4 + Vβ expression were found among the three age groups of healthy Greek children studied.
* IQR Interquartile range (75th - 25th percentile).
† The numbers in brackets indicate the two age groups that were used for the comparison with the corresponding p-value.
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were two SLE patients with a normal repertoire at initial
diagnosis. When statistical analysis was performed in
order to compare the CD4 + Vβ expression between SLE
and healthy children, significant differences in TCR Vβ
quantitative expression were noticed only for the Vβ16
chain (p <0.001) (Table 3, Figure 6). This was expected,
since five SLE patients presented with higher values of
the CD4 + Vβ16 chain than those of the control group
(mean value + 3SD) (Figure 7). Only one healthy indi-
vidual presented an increased usage of CD4 + Vβ16, but
he displayed no other discrepancies of the rest CD4 +
Vβ subfamilies.
d) Findings of T lymphocyte populations by flow
cytometric analysis
The basic immunophenotyping findings of the T1DM
and SLE groups, when compared to controls, were asfollows: a) Increased expression of CD69 molecule in
two SLE patients and in one T1DM patient, b) elevated
percentage of the CD3+ TCRγδ lymphocyte population
(20%) in two SLE patients, c) increased expression of
the HLA-DR + cells in 2 of the nine SLE children tested
and d) absolute number of B lymphocytes (CD19+) be-
yond normal values in one SLE and in one T1DM pa-
tient. No difference in the CD5 + CD19+ expression was
noticed among the three groups and the values (%) of the
CD5 + CD19+ populations ranged between 0.1 and 1.2%
in all individuals tested.
Discussion
Flow cytometric analysis of the CD4 + TCR Vβ reper-
toire performed in three different groups of children of
Greek origin, healthy, T1DM and SLE ones, provided re-
sults similar to previous published studies, but with some
differences.
Table 3 CD4 + Vβ chains usage in T1DM children
T1DM
children
CD4+ TCR Vβ Increased
usage
CD4 + TCR Vβ Decreased
usage
Patient 1 Vβ5.1 (7.3%, Μ + 2SD) None
Patient 2 Vβ5.3 (5.8%, Μ + 3SD) None
Patient 3 Vβ16 (5%, Μ + 3SD) None
Vβ5.1 (7.5%, Μ + 2SD)
Vβ8 (6.5%, Μ + 2SD)
Vβ21.3 (4.1%, Μ + 2SD)
Patient 4 None None
Patient 5 Vβ16 (5.5%, Μ + 3SD) Vβ14 (0.7%, Μ-2SD)
Vβ18 (4.1%, Μ + 3SD)
Vβ11 (3.1%, Μ + 2SD)
Patient 6 None None
Patient 7 None None
Patient 8 Vβ3 (11.2%, Μ + 3SD) None
Patient 9 Vβ4 (2.6%, Μ + 3SD) None
Patient 10 None None
Patient 11 Vβ4 (2.3%, Μ + 2SD) None
Patient 12 Vβ4 (2.1%, Μ + 2SD) None
Patient 13 None None
Patient 14 Vβ4 (2.2%, Μ + 2SD) None
Patient 15 Vβ5.1 (9.1%, Μ + 3SD) Vβ20 (0.5%, Μ-2SD)
Vβ4(3.3%, Μ + 3SD)
CD4 + TCR Vβ repertoire observed in T1DM patients in comparison to controls was
similar. Low usage of the Vβ chains is rarely found in patients with T1DM.
Figure 2 CD4 + TCR Vβ values (%) in T1DM children. CD4 + TCR Vβ repe
in healthy children with the exception of Vβ4 subpopulation.
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this study support the non-random usage of TCR Vβ
subfamilies in Greek children, as observed in previous
studies on normal adults and children [11,16,17]. There
is also no statistical difference in T cell repertoire among
the three pediatric age groups studied and this is in ac-
cordance to another pediatric population studied in the
United Kingdom [11]. Many healthy individuals had also
sporadically increased expression of CD4 + Vβ chains as
previously shown [11,16,17]. To our knowledge, analysis
of the CD4 + Vβ repertoire expression pattern in Greek
adults has not been conducted so far, so comparison
with values of adults of the same ethnic origin could not
be performed.
T1DM children had an almost same CD4 + Vβ reper-
toire pattern with healthy individuals, with the exception
of the CD4 + Vβ4 chain which had increased expression
in T1DM patients when compared to controls. Previous
studies have shown similar results, that is either no dif-
ferences between the two groups [12], or increased usage
of other chains like the Vβ7 one [13,18]. Some putative
explanations for the absence of consistency in the results
among several studies could be the scarcity of published
studies in human populations, the small size of the sam-
ples tested both in our study and others, as well as the
different methodologies applied for the TCR repertoire
assessment. It is still unclear though, whether the in-
creased expression of CD4 + Vβ4 in newly diagnosed
T1DM children of Hellenic origin is a constant findingrtoire usage (values %) in T1DM children resembles the one observed
Table 4 Results of statistical analysis between T1DM
children and controls and SLE children and controls
Group
Controls SLE T1DM
Median iqr Median iqr p Median iqr p
Vb3 4.40 3.60 5.60 2.40 .200 4.20 3.20 .833
Vb5.3 1.60 1.10 1.40 1.00 .661 1.70 1.10 .851
Vb7.1 1.60 1.50 1.70 1.40 .475 2.20 1.00 .181
Vb16 1.95 1.40 5.62 4.30 <.001 2.60 3.60 .252
Vb9 2.50 1.40 3.60 2.60 .019 4.10 2.10 .002
Vb17 4.20 1.70 2.40 3.26 .029 3.80 2.30 .515
Vb20 3.80 3.00 3.85 2.75 .543 2.90 2.70 .044
Vb18 1.20 1.50 1.00 1.00 .464 1.80 1.90 .027
Vb5.1 4.20 2.30 4.00 2.40 .498 6.30 2.00 .003
Vb8 3.90 1.60 2.80 2.90 .175 3.70 1.70 .302
Vb13.1 3.90 1.50 5.10 1.10 .067 4.40 .70 .119
Vb13.6 1.80 .80 1.80 1.40 .791 2.00 .50 .145
Vb12 4.50 1.80 6.30 4.64 .013 4.70 3.10 .879
Vb5.2 1.10 .90 1.70 1.20 .650 1.20 .80 .438
Vb2 7.40 3.70 7.00 4.67 .318 7.90 2.50 .815
Vb21.3 2.60 1.00 3.48 .80 .006 2.60 .50 .605
Vb23 .80 1.10 .95 .51 .986 1.10 .90 .557
Vb1 3.10 .80 3.45 2.05 .564 3.00 1.40 .869
Vb14 3.70 2.00 3.35 3.09 .835 2.40 1.30 .001
Vb11 1.40 1.00 1.79 1.40 .169 1.30 1.00 .842
Vb22 2.70 1.10 2.10 2.22 .085 3.10 1.80 .236
Vb7.2 1.70 1.70 3.15 1.45 .010 1.80 1.80 .241
Vb13.2 2.20 1.50 3.25 1.35 .012 3.20 1.40 .017
Vb4 .70 .70 1.15 2.04 .542 1.50 .80 <.001
Statistical analysis of the CD4+ TCR Vβ lymphocytes between a) SLE patients and
controls, b) T1DM patients and controls. Only the Vβ16 chain presented with
significantly increased usage in SLE children and the Vβ4 chain in T1DM ones.
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longitudinal studies are required to clarify this issue. A
similar confirmed polymorphism of the TCRV20S1 gene
was found in the healthy Sardinian population, but fur-
ther research failed to relate this polymorphism with the
high incidence of T1DM in Sardinians [19].
In contrast to T1DM patients, in SLE patients skewing
of the CD4 + Vβ repertoire is far more prominent. This
finding is in accordance to previous studies published in
adults [14,15]. CDR3 spectratyping performed in the
peripheral blood of 20 adult SLE patients has shown a
prominent usage of the Vβ16 chain among other Vβ
subpopulations (Vβ2, Vβ8, Vβ11, Vβ14, Vβ19 and Vβ24)
[15]. In the present study, in which flow cytometry was
used, increased usage of the Vβ16 chain in the CD4+ T
cells of peripheral blood was found in the majority of
SLE children. Higher values of other CD4+ Vβ chainswere also noticed in SLE children in comparison to
healthy ones, but they concerned individual patients.
Our results are difficult to compare with previous studies
published in adults, not only because of the different meth-
odologies used (flow cytometry versus spectratyping) or
to different samples studied (children versus adults, pa-
tients at initial diagnosis versus patients under treat-
ment) but also because of the limited number of the
studies conducted in that field. Larger scale analysis in
populations categorized according to age, to time of the
study held (before or after treatment), to sex, to ethni-
city and to methodology used could provide further
insight on the role of Vβ repertoire not only in auto-
immune disease pathogenesis but also in its clinical sig-
nificance as a prognostic factor in the case of SLE.
Limitations of the present study are the limited num-
ber of the patients studied, but this is due to the rarity
of lupus in children in the Greek population and to the
fact that only patients upon the initial diagnosis were se-
lected in order to avoid alterations in their immuno-
logical profile that medication could induce. Another
parameter is the fact that evaluation of the Vβ repertoire
in each patient is not influenced by the number of the
patients investigated. Although genetic evaluation was
not performed, all previous published studies in immune
mediated diseases have showed that there are no dis-
crepancies between the results from flow cytometric
analysis and spectratyping, enhancing the reliability of
flow cytometry. Finally, the CD8+ Vβ lymphocyte sub-
populations were not analyzed, and therefore it is not
known whether there are abnormalities in the repertoire
of children with diabetes or lupus or not.
As far as immunophenotyping analysis is concerned,
no major differences among the groups were noticed.
Regarding the role of the CD5 + CD19+ population in
autoimmune process, its expression was quite similar in
the three groups studied. This finding is in accordance
with other studies in adult SLE patients, but not with
studies in T1DM patients, in whom increased expression
was observed [20,21].
Conclusions
This is the first comparative flow cytometric analysis be-
tween an organ-specific autoimmune disease, T1DM,
and a systemic one, SLE, which underscores the import-
ance of the TCR Vβ repertoire in patients with auto-
immune diseases. This study was possible because of the
availability of an easily applicable method at a clinical
setting, which enabled TCR Vβ repertoire analysis prior
to initiation of any treatment that could possibly be a
confounding factor. Abnormalities of the CD4+ TCR Vβ
repertoire quantitative expression were observed mainly
in SLE children. Low usage of certain CD4 + TCR Vβ
chains was also far more prominent in lupus patients.
Figure 3 Comparison of CD4+ Vβ repertoire between T1DM and healthy children. Median values of the CD4+ TCR Vβ repertoire in healthy
children and in children with T1DM are presented. The CD4 + Vβ4 chain presented with a significantly increased expression (p < 0.001) when
compared to healthy age-matched individuals.
Figure 4 Comparison of CD4 + Vβ4 chain values among the 3 groups of children studied. Values (%) of the CD4 + Vβ4 chain are higher in the
majority of T1DM children in comparison to controls.
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Table 5 Adjusted statistical analysis in CD4 + Vβ4 chain
Vβ4 Group Mean Std. Err. Std. Dev. [95% Conf. Interval]
Controls 0.797 0.097 0.541 0.598 0.995 <.001
T1DM 1.740 0.183 0.710 1.347 2.133
Vβ4 Group “New” mean Std. Err. Std. Dev. [95% Conf. Interval] p
Controls 0.956 +20% of the original value 0.097 0.541 0.598 0.995 0.026
T1DM 1.392 -20% of the original value 0.183 0.710 1.347 2.133
Adjustment of statistical analysis for the CD4 + Vβ cells for a maximum CV of 20% showed that differences between healthy controls and T1DM children remained
significant. CV: coefficient of variation.
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cytes were significantly increased in T1DM and SLE chil-
dren, respectively. However, the potential role of these
lymphocyte clones in the pathogenesis of autoimmunity
remains to be clarified.Methods
Subjects
Samples were collected from a) Fifteen newly diagnosed
children with T1DM (mean age ± SD: 9.2 year ± 4.78, 11
males-4 females) during their hospitalization upon diagno-
sis in the First Department of Pediatrics of the University
of Athens in “Aghia Sophia” Children’s Hospital and b)
Nine patients with SLE (mean age ± SD: 12.8 years ± 1.76,
3 males-6 females) upon diagnosis and prior to treatment
initiation, all of Hellenic origin. Thirty one healthy Greek
children (mean age ± SD: 6.58 years ± 3.65, 26 males-5Table 6 Skewing of the CD4 +Vβ repertoire in SLE children




CD4 + TCR Vβ
decreased usage
Patient 1 None None
Patient 2 Vβ16 (7.4%, Μ + 3SD) None
Patient 3 Vβ4 (2.4%, Μ + 3SD) Vβ18 (0%, Μ-2SD)
Patient 4 Vβ16 (8.2%, Μ + 3SD) Vβ8 (0.3%, Μ-3SD)
Vβ13.6 (0%, Μ-3SD)
Patient 5 Vβ13.2 (7.4%, Μ + 3SD)
Vβ4 (2.7%, Μ + 3SD)
Patient 6 Vβ16 (5.6%, Μ + 3SD) Vβ5.1 (0.12%, Μ-2SD)
Vβ2 (2.83%, Μ-2SD)
Vβ20 (9.17%, Μ + 3SD)
Vβ12 (9.44%, Μ + 3SD)
Patient 7 None None
Patient 8 Vβ16 (8%, Μ + 3SD) Vβ22 (0%, Μ-2SD)
Vβ20 (7.5%, Μ + 2SD)




Vβ16 (7.3%, Μ + 3SD)
Vβ12 (14.2%, Μ + 3SD)
Discrepancies of the CD4+ TCR Vβ repertoire observed in SLE patients at initial
diagnosis. M mean value (derived from controls sample), SD standard deviation.females) undergoing minor surgery at the First and Second
Department of Surgery at “Aghia Sophia” Children’s Hos-
pital were included as controls. Taking into account that
several germ line polymorphisms of the TCR Vβ genes
have been described in different ethnicities [22,23], this
study was restricted to children of Greek origin in order to
include an ethnically homogeneous population. A stan-
dardized interview was held with parents of all children.
Ethical approval
The study was approved by the Ethical Committee of
the “Aghia Sophia” Children’s Hospital and participants
were included in the study only after informed consent
was obtained from their parents or guardians.
Methodology
Blood (4 ml in EDTA tube and 3 ml serum) was taken
from all participants for investigations, including full
blood count, serum immunoglobulin levels assessment by
nephelometry and screening for autoantibodies by indirect
immune-fluorescence (ANA, anti-dsDNA, ICA), as well as
lymphocyte subpopulation immunophenotyping by flow
cytometry.
Flow cytometry
CD4 + TCR Vβ repertoire was analyzed using three-
color flow cytometry with the IOTest Beta Mark TCR
Repertoire Kit (Beckmann Coulter, Marseille, France),
which consists of fluorochrome conjugated monoclonal
antibodies that identify 24 TCR Vβ subfamilies, covering
about the 70% of the normal human CD4+ T cells. Since
at the time of the study initiation, only three-color flow
cytometry was in practice, and in order to assess the re-
sults with the same method, no changes in methodology
were undertaken. For that reason only the CD4+ TCR
Vβ repertoire and not the CD8+ one was assessed. Per-
ipheral blood samples were collected in tubes containing
anticoagulant (EDTA) and were stained within 2 hours.
100 μl of blood was incubated for 20 minutes, at room
temperature with 20 μl of a mixture of three distinct anti-
Vβ monoclonal antibodies and 10 μl of anti-CD4-PC5
monoclonal antibody (MoAb). Erythrocytes were lysed by
Figure 5 CD4 + TCR Vβ repertoire usage in SLE children. CD4 + TCR Vβ repertoire usage (values %) in SLE children is quite different to the one
of healthy children and T1DM patients. Many SLE children had very low usage of several Vβ chains.
Figure 6 Comparison of CD4+ Vβ repertoire between SLE and healthy children. Median values of the CD4+ TCR Vβ repertoire in healthy
children and in children with SLE are presented. The CD4 + Vβ16 chain presented with a significantly increased expression (p < 0.001) when
compared to healthy age-matched individuals.
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Figure 7 Comparison of CD4 + Vβ16 chain values among the 3 groups of children studied. Values (%) of the CD4 + Vβ16 chain are higher in
the majority of SLE children in comparison to controls.
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collected for analysis. CD4+ lymphocytes were gated using
forward scatter, side scatter and FL4 fluorescence; whereas
Vβ repertoire analysis used two additional fluorescence
channels (FL1 and FL2).
Data acquisition was performed initially on an EPICS
XL (Beckman Coulter) flow cytometer and, later on, on an
FC-500 (Beckman Coulter), instrument. Listmode analysis
was performed using the CXP software.
Lymphocyte subpopulations tested were: 1) CD3+ T
cells, 2) helper T cells (CD3 + CD4+), 3) cytotoxic T cells
(CD3 + CD8+), 4) natural killer cells (CD56+) and 5) B
lymphocytes (CD19+). Moreover, the αβ and γδ expres-
sion on T cells, the expression of CD69+ and HLA-DR +
on T cells as activation markers and the expression of
CD5+ on CD19+ B cells were studied.
Statistical analysis
Statistical analysis among three age groups of the healthy
individuals included in the study was performed in order to
detect possible skewing among them. Age was transformed
to categorical variables, thus constructing three age groups:
18 months-411/12 years (n = 12), 5-911/12 years (n = 10)
and ≥ 10 years (n = 9). The reason for this transformation
was to reveal a possible difference in Vβ repertoire usage
among specific age groups that roughly reflect the stages
of child development and immune system maturation. Vβ
repertoire expression variables are described as median
and interquartile range IQR (75th-25th percentile) due tothe small sample size and to their non-normal distribu-
tion. For the same reason, non parametric statistics were
used; Mann–Whitney U statistic was used for the com-
parison of the aforementioned variables between two age
subgroups and Kruskal-Wallis rank test when comparing
the same variables among the three age subgroups of the
study. All tests were two-sided at a significance level of
p < 0.5. Data were analyzed using STATA™ (Version 9.0,
Stata Corporation, College Station, TX 77845, USA).
To assess the possible differences of CD4 + TCR Vβ
repertoire expression, pediatric patients with newly diag-
nosed SLE and T1DM were compared with healthy age-
matched controls. Due to the small subgroup sizes of
SLE and T1DM (n = 9, n = 15 respectively), median and
IQR (75th - 25th percentile) were used to describe the
continuous variables. In addition, nonparametric statis-
tical analysis (Mann–Whitney U) was used to test for
any significant differences between the subgroups. Due
to the multiple comparisons (n = 24), Bonferroni adjust-
ment was performed in order to correct for inflation in
type I error, setting the significance level from p < 0.05
to < 0.0021 (=0.05/24). Statistical analysis was also
adjusted to a CV of 20%, which could characterize the
results of Vβ chains with rare expression. The significant
difference that was found between controls and T1DM
patients in Vβ4 chain was also present when using
Student’s t-test for the comparison. Although t-test is a
parametric statistic and less powerful in our case due to
the small number of patients, it allowed us to perform
Tzifi et al. BMC Immunology 2013, 14:33 Page 11 of 12
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tioned groups in order to verify that the comparisons
would remain significant even after increasing the mean
value in the control group by 20% and decreasing the
mean value in the T1DM group (for Vβ4 chain) by 20%.
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